Evidence map›Paper›PMID 38093515›Full record

ArticleThoracic cancer2024

Different effects of crizotinib treatment in two non-small cell lung cancer patients with SDC4::ROS1 fusion variants.

Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Yuta OhishiNihon University Itabashi Hospital, Tokyo, Japan.
Yoko NakanishiDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.ORCID 0000-0001-5022-4676
Yukari HirotaniDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Atsuko SuzukiDivision of Pathology Laboratory, Nihon University Itabashi Hospital, Tokyo, Japan.
Tomoyuki TaninoDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Haruna Nishimaki-WatanabeDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Hiroko KobayashiDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Fumi NozakiDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Sumie OhniDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Xiaoyan TangDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Kentaro HayashiDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Yoshiko NakagawaDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.ORCID 0000-0003-4807-3797
Tetsuo ShimizuDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.ORCID 0000-0003-3405-9652
Ichiro TsujinoDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Noriaki TakahashiDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Yasuhiro GonDivision of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, Tokyo, Japan.
Shinobu MasudaDivision of Oncologic Pathology, Department Pathology and Microbiology, Nihon University School of Medicine, Tokyo, Japan.
Nihon University · JPNihon University Itabashi Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The possibility of stratifying patients according to differences in ROS proto-oncogene 1 (ROS1) fusion partners has been discussed. This study aimed to clarify the clinicopathological differences between two SDC4::ROS1 positive NSCLC cases who had different responses to crizotinib. Cytology and pathology samples from two NSCLC cases with SDC4::ROS1 who were diagnosed and treated with crizotinib at Nihon University Itabashi Hospital were obtained. Case 1 has been well-controlled with crizotinib for over 5 years, but case 2 was worse and overall survival was 19 months. Sequencing analysis of ROS1 fusion genes was performed by reverse-transcription-PCR and Sanger's sequencing methods. In addition, thyroid transcription factor (TTF)-1, ROS-1, Ki67, and phosphorylated extracellular signal-regulated kinase (pERK)1/2 expression were investigated using immunohistochemistry. Sequencing analysis showed SDC4 exon2::ROS1 exon 32 (exon33 deleted) in case 1, and coexistence of SDC4 exon2::ROS1 exon 34 and SDC4 exon2::ROS1 exon35 in case 2. The Ki67 index was not different, but ROS1 and pERK1/2 expression levels tended to be higher in the tumor cells of case 2 than in case 1. Therapeutic response to crizotinib and patients' prognosis in ROS1 rearranged NSCLC may be related to the activation of ROS1 signaling, depending on ROS1 and pERK1/2 overexpression status, even if the ROS1 fusion partner is the same.

Indexed as

Carcinoma, Non-Small-Cell LungCrizotinibLung NeoplasmsHumansKi-67 AntigenProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsReactive Oxygen SpeciesSyndecan-4CrizotinibKi-67 AntigenProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene ProteinsReactive Oxygen SpeciesROS1 protein, humanSDC4 protein, humanSyndecan-4ERK1/2NSCLCprognosisROS1treatment effects

Identifiers

PMID38093515
PMCPMC10761618
OpenAlexW4389741782

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.